Mounjaro and the Oral Contraceptive Pill: Does Tirzepatide Affect Your Contraception?

If you take the combined oral contraceptive pill and have recently started Mounjaro (tirzepatide), you may be wondering whether the two work safely together. It is a fair question, and the answer matters more than many patients realise.

Tirzepatide slows gastric emptying, the rate at which your stomach passes its contents into the small intestine. Because oral contraceptive pills are absorbed in the gut, that delay can reduce how much of the active hormones reach your bloodstream. The result is a measurable drop in contraceptive efficacy during the early weeks of treatment and after every dose increase.

Below, we explain exactly what the clinical data shows, what the Faculty of Sexual and Reproductive Healthcare (FSRH) recommends, and what practical steps you should take to stay protected while on Mounjaro.

Yes. Tirzepatide reduces the absorption of oral contraceptive hormones. Clinical pharmacokinetic studies show a 20% reduction in the total exposure (AUC) of ethinylestradiol and a 21% reduction for norgestimate when taken alongside a single 5 mg dose of tirzepatide. Peak blood levels (Cmax) fell even further, by up to 59% for ethinylestradiol and 66% for norgestimate.

The FSRH advises anyone starting Mounjaro to use an additional barrier method of contraception, such as condoms, for four weeks after initiation and for four weeks after each dose escalation. Non-oral forms of contraception, including the implant, hormonal coil (IUS), injection, and patch, are not affected.

Mounjaro is a dual GIP and GLP-1 receptor agonist. One of its key mechanisms for weight loss is slowing the speed at which food and fluids leave the stomach, a process called delayed gastric emptying. This is also the reason many patients feel fuller for longer after meals.

The practical consequence for oral medications is straightforward: if a tablet sits in the stomach for longer before reaching the small intestine, its absorption can be delayed and, in some cases, reduced. For medications taken daily at steady state, such as blood pressure tablets or statins, the clinical impact is usually negligible. The total drug still gets absorbed over 24 hours.

Oral contraceptive pills are different. Their efficacy depends on maintaining a tight hormonal window. Even a modest dip in peak hormone levels can, theoretically, allow a breakthrough ovulation event. That is why the regulators treat this interaction with more caution than most other oral drug combinations.

The pivotal pharmacokinetic study administered a combined oral contraceptive containing 0.035 mg ethinylestradiol and 0.25 mg norgestimate alongside a single 5 mg dose of tirzepatide. The findings were significant:

• Ethinylestradiol AUC reduced by 20%, Cmax reduced by 59%
• Norgestimate AUC reduced by 21%, Cmax reduced by 66%
• Norelgestromin (the active metabolite of norgestimate) AUC reduced by 23%, Cmax reduced by 55%
• Time to peak concentration (Tmax) was delayed by 2.5 to 4.5 hours

These reductions were observed after a single 5 mg dose. The Mounjaro Summary of Product Characteristics (SmPC) notes that the effect on gastric emptying is dose-dependent, meaning higher doses of tirzepatide may produce a greater effect. However, subsequent doses at the same level tend to show a diminished impact as the body adapts.

Importantly, no large-scale clinical trial has directly measured unintended pregnancy rates in women taking both tirzepatide and the pill. The recommendation to use barrier contraception is based on the pharmacokinetic data and the precautionary principle, which is the standard regulatory approach for interactions of this nature.

In February 2025, the FSRH published a formal statement on GLP-1 receptor agonists and oral contraception. The key recommendations are:

• Use an additional barrier method (such as condoms) for four weeks after starting tirzepatide
• Use an additional barrier method for four weeks after each dose increase
• If you experience severe vomiting or diarrhoea while on Mounjaro, follow existing FSRH missed-pill and vomiting/diarrhoea guidance

The FSRH explicitly noted that tirzepatide is the only GLP-1 receptor agonist with a clinically significant effect on oral contraceptive absorption. If you are taking semaglutide (Ozempic or Wegovy), dulaglutide, exenatide, or liraglutide, no additional barrier method is required on the basis of this interaction alone.

At CutKilo, we discuss contraception with every female patient of reproductive age during the initial medical consultation. If you are prescribed Mounjaro and currently rely on the combined pill or the progesterone-only pill for contraception, your prescribing doctor will advise you on barrier protection and, where appropriate, discuss whether switching to a non-oral method might be a simpler long-term solution.

Because the interaction is driven by delayed gastric emptying, any contraceptive that bypasses the gut entirely is unaffected. The following methods deliver hormones directly into the bloodstream or act locally, and do not rely on oral absorption:

• Hormonal coil (IUS/Mirena): releases levonorgestrel directly into the uterus
• Subdermal implant (Nexplanon): releases etonogestrel from a rod inserted under the skin of the upper arm
• Depo-Provera injection: intramuscular depot of medroxyprogesterone acetate
• Contraceptive patch (Evra): transdermal delivery of ethinylestradiol and norelgestromin
• Vaginal ring (NuvaRing): releases ethinylestradiol and etonogestrel via the vaginal mucosa
• Copper IUD: non-hormonal, works by creating a hostile environment for sperm

If you are planning to start Mounjaro and would prefer not to use condoms for four weeks at every dose change, discussing a switch to one of these methods with your GP or sexual health clinic before starting treatment may be the most practical option.

If you rely on emergency contraception at any point during Mounjaro treatment, be aware that oral emergency contraceptive pills (levonorgestrel, sold as Levonelle, and ulipristal acetate, sold as ellaOne) are also absorbed through the gut. Delayed gastric emptying could, in theory, reduce their efficacy, although no specific pharmacokinetic data exists for this combination.

The copper intrauterine device (IUD) is the most effective form of emergency contraception and is entirely unaffected by tirzepatide. It can be fitted up to five days after unprotected intercourse and has a failure rate of less than 1%. If you are taking Mounjaro and need emergency contraception, a copper IUD fitted at a sexual health clinic or your GP surgery is the recommended first-line option.

If a copper IUD is not accessible, an oral emergency contraceptive is still better than no intervention. Take it as soon as possible and inform the pharmacist or prescriber that you are taking tirzepatide.

Not all injectable weight loss medications carry the same risk. Semaglutide (the active ingredient in Ozempic and Wegovy) was studied in similar pharmacokinetic trials and showed no clinically meaningful reduction in oral contraceptive absorption. The same is true for dulaglutide (Trulicity), liraglutide (Saxenda), and exenatide (Byetta/Bydureon).

The reason tirzepatide behaves differently is its dual agonism. By activating both GIP and GLP-1 receptors, it produces a more pronounced delay in gastric emptying than pure GLP-1 receptor agonists, particularly at higher doses. This pharmacological distinction is the basis for the FSRH singling out tirzepatide in its guidance.

If you are considering switching from semaglutide to tirzepatide, your prescriber should discuss the contraceptive interaction at the point of switch. The four-week barrier method recommendation applies from the first tirzepatide injection, regardless of your prior GLP-1 history.

Tirzepatide is the only GLP-1 receptor agonist with a proven, clinically significant effect on oral contraceptive absorption. The single most important thing to know is this: use condoms or another barrier method for four weeks after starting Mounjaro and for four weeks after every dose increase. If that feels impractical, ask your GP about switching to a non-oral contraceptive before you begin treatment.

At CutKilo, we raise this conversation proactively with every female patient of reproductive age. Unintended pregnancy is an avoidable risk, and the solution is simple. Your weight loss journey should never come at the expense of your reproductive health.

Does Mounjaro stop the pill from working completely? No. Mounjaro reduces the absorption of oral contraceptive hormones by around 20%, but it does not eliminate their effect entirely. The concern is that this reduction may be enough to allow breakthrough ovulation in some women, which is why the FSRH recommends adding a barrier method during the high-risk windows.

Do I need to use condoms the entire time I am on Mounjaro? No. The FSRH advises barrier contraception for four weeks after starting tirzepatide and for four weeks after each dose increase. Once you have been stable on the same dose for more than four weeks, the additional barrier method is no longer required, assuming no severe vomiting or diarrhoea.

Is the contraceptive patch affected by Mounjaro? No. The contraceptive patch (Evra) delivers hormones through the skin and bypasses the gut entirely. It is not affected by delayed gastric emptying and requires no additional precautions while on Mounjaro.

Should I take my pill at a different time of day while on Mounjaro? There is no specific guidance on timing. The absorption delay is related to gastric emptying speed, not the time interval between the injection and the pill. Taking your pill at the same time every day, as usual, remains the best practice.

What if I have been on Mounjaro for months and did not know about this interaction? If you have been on a stable dose for more than four weeks without any episodes of severe GI symptoms, the risk of contraceptive failure is considered low. If you have any concerns, speak to your prescribing doctor or contact the CutKilo clinical team for advice.